This document outlines the essential safety and efficacy data that developers must generate during the "non-clinical" (animal or lab) phase to justify moving into human subjects.
The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) .
: Evaluating whether the viral vector or therapeutic gene could unintentionally be passed on to future generations. 125459
Guideline on the Non-Clinical Studies Required before First ... - EMA
For more detailed technical specifications, you can access the full Guideline on Non-Clinical Studies for GTMPs via the official . This document outlines the essential safety and efficacy
: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA.
: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements : Guideline on the Non-Clinical Studies Required before First
The guideline, officially titled , provides a framework for non-clinical studies required before a gene therapy can be used in human clinical trials. Guide to EMA Guideline 125459